Myhep All Tablet

Chronic hepatitis C (HCV) infection.

Myhep All tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional. If you've had hepatitis B in the past, taking Myhep All Tablet can make the virus active again. Before you start treatment your doctor will test you for hepatitis B and, if necessary, monitor you closely. Some common side effects are:

• Anemia
• Headache
  
• Fatigue
• Nausea
• Insomnia
• Diarrhea
• Itching
• Decreased appetite
• Muscle or joint pain
  
• Dizziness
  

Take this medicine exactly as directed by your doctor, in the prescribed dose and for the recommended duration. Swallow the whole tablet, do not chew, crush, or break it. Myhep All Tablet can be taken with or without food, but it is best to take it at the same time each day.

• Sofosbuvir and Velpatasvir are two antiviral medications that are combined in Myhep All Tablet.
• They function by gradually removing the hepatitis C virus from the blood and reducing its levels in the body.
• By focusing on a particular protein required for viral reproduction, the direct-acting antiviral medication (DAA) sofosbuvir prevents the HCV virus from replicating.
• Another DAA that functions by preventing the activity of a different protein implicated in HCV replication is velpatasvir.
  

If you miss a dose of Myhep All Tablet, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing routine. Do not take a double dose to make up for the missed one.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Butt, N., Muhammad, I., Abou Bakr, A., Akhtar, Z., Ali, M., & Maheshwary, N. (2020). Efficacy and safety of Sofosbuvir-velpatasvir combination in Pakistani HCV patients without or with compensated cirrhosis. Cureus, 12(1), e6537. https://doi.org/10.7759/cureus.6537
  
• Goel, A., Chen, Q., Chhatwal, J., & Aggarwal, R. (2018). Cost-effectiveness of generic pan‑genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment in India. Journal of Gastroenterology and Hepatology, 33(12), 2029–2036. https://doi.org/10.1111/jgh.14301
  
• Tan, Y. M., et al. (2023). Real‑world impact of the subsidy decision of sofosbuvir‑velpatasvir for chronic hepatitis C: trends in utilization and SVR outcomes in Malaysia. JGH Open. https://doi.org/10.1002/jgh3.12850
  
• Springer. Gaur, N., et al. (2020). Sofosbuvir‑velpatasvir fixed-dose combination for chronic hepatitis C infection in end-stage renal disease patients on maintenance hemodialysis: An Indian single-center experience. Journal of Clinical and Experimental Hepatology. Retrieved from PubMed. Shah, V., et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for retreatment of difficult-to-treat chronic HCV patients in India: Real-life observational cohort. Journal of Clinical and Experimental Hepatology. https://pubmed.ncbi.nlm.nih.gov/38261859/
  
• Huang, C.-T., et al. (2021). Sofosbuvir/velpatasvir for chronic hepatitis C virus infection: real‑world effectiveness and safety from a nationwide registry in Taiwan. Infectious Diseases and Therapy, 10(3), 1185–1196. https://doi.org/10.1007/s40121-021-00576-7